Papillary Thyroid Cancer Clinical Trial
Official title:
CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer
Localized thyroid cancer is potentially curable. Before thyroid surgery, an ultrasound test is done to see if cancer has spread to the lymph nodes in the neck. Excellent for evaluation of the thyroid gland, this test has limitations in evaluating larger anatomic areas, like all groups of lymph nodes in the neck. It has a limited area of coverage making it difficult to define an area of interest, depends on the skill level of the person performing it, and is difficult to exactly reproduce on follow-up. For these reasons, CT is often performed in these patients but without intravenous (IV) contrast since iodine-based contrast agents may saturate the thyroid, limiting the usefulness of other iodine-based diagnostic and treatment options. However, contrast-CT can give more detailed information about tumor spread including spread to lymph nodes. We aim to determine if use of IV contrast agent during CT leads to earlier and more accurate detection of lymph node disease from thyroid cancer.
Papillary thyroid cancer represents 75% of all epithelial thyroid malignancies. Imaging not
only delineates the primary tumour within the thyroid gland, but also helps assess lymph
nodal metastatic disease helping guide the extent of surgical neck dissection.
Ultrasonography (US) is the current imaging standard (American Thyroid Association
guidelines). However, US is limited by operator skills and lacks specific anatomic references
essential to plan surgery. CT is performed to address these issues, often without intravenous
(IV) contrast for fear of saturating thyroid tissue with iodine present in it, thus rendering
iodine-labeled nuclear testing/treatment ineffective for a finite period of time. But
post-contrast nodal enhancement is a predominant morphologic feature of suspicious
lymphadenopathy in papillary thyroid cancer, and contrast-CT can facilitate an earlier
detection. Iodine-saturation is not a concern in these patients as its concentration will
normalize during recovery.
In pre-surgical thyroidectomy patients with proven papillary thyroid cancer, the use of
intravenous (IV) CT contrast improves the reliability and accuracy of suspicious head and
neck lymph node detection, in comparison to CT without IV contrast.
This study will help define the accuracy and reliability of intravenous (IV) contrast use in
the detection of metastatic neck lymph nodes from papillary thyroid cancer. Improved
detection of suspicious metastatic lymphadenopathy in papillary thyroid cancer will directly
impact the patient's management since the surgical plan will be based upon the detection of
these suspicious lymph nodes. CT imaging provides an anatomically relevant approach to
surgery and is consistently reproducible, thus providing direct benefits to the pre-surgical
assessment. Ultimately, this will result in decreased nodal recurrences within the neck.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01441154 -
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
|
||
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03469011 -
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
|
Phase 1 | |
Recruiting |
NCT05752669 -
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
|
||
Recruiting |
NCT04076514 -
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
|
||
Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
Unknown status |
NCT02140476 -
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy
|
N/A | |
Recruiting |
NCT06286631 -
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
|
||
Completed |
NCT06325787 -
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
|
N/A | |
Terminated |
NCT01974284 -
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
|
N/A | |
Active, not recruiting |
NCT00984191 -
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
|
N/A | |
Active, not recruiting |
NCT04731467 -
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
Completed |
NCT02178345 -
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
|
||
Not yet recruiting |
NCT06133374 -
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
|
||
Completed |
NCT03470259 -
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
|
Phase 1 | |
Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A |